Analysts are hoping that GlaxoSmithKline plc (ADR) (NYSE:GSK) can stabilize the company amid a series of new strategies that the CEO, Andrew Witty, has been implementing in recent months. Bernstein analyst Tim Anderson has reviewed the company that decided to let go of the cancer treatment drugs and focus instead on the vaccine groups. Anderson […]
